La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Forward Pharma A/S ADR a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Forward Pharma A/S ADR..

Forward Pharma A/S ADR (OTC:FWPAY) Azioni, Catena delle Opzioni

Forward Pharma A/S ADR

Morgan Stanley analyst Andrew Percoco maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Equal-Weight and lowers the price target from $93 to $74.

News

Price Target

Analyst Ratings

ENPH

Morgan Stanley Maintains Equal-Weight on Enphase Energy, Lowers Price Target to $74

JMP Securities analyst Brian McKenna maintains Blue Owl Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Market Outperform and raises the price target from $25 to $27.

JMP Securities Maintains Market Outperform on Blue Owl Cap, Raises Price Target to $27

WIIM

Flexible Solutions shares are trading higher. The company reported Q3 financial results.

SLGL

Sol-Gel Technologies shares are trading higher after the company reported better-than-expected Q3 financial results.

JMP Securities analyst Aaron Hecht maintains Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Market Outperform and lowers the price target from $140 to $130.

JMP Securities Maintains Market Outperform on Alexandria Real Estate, Lowers Price Target to $130

Morgan Stanley analyst Stephen Byrd maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Overweight and lowers the price target from $35 to $27.

Morgan Stanley Maintains Overweight on Sunrun, Lowers Price Target to $27

Progressive shares are trading higher after the company reported a year-over-year increase in Q3 financial results.

Morgan Stanley analyst Andrew Percoco maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $301 to $367.

Morgan Stanley Maintains Overweight on GE Vernova, Raises Price Target to $367

CERO

CERo Therapeutics shares are trading higher after the company received FDA clearance for its investigational new drug application to initiate a Phase 1 clinical trial of CER-1236 for acute myelogenous leukemia.

Cantor Fitzgerald analyst Andres Sheppard maintains Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a Overweight and raises the price target from $10 to $15.

LUNR

Cantor Fitzgerald Maintains Overweight on Intuitive Machines, Raises Price Target to $15

CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia

Evercore ISI Group analyst Mark Lipacis maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Outperform and lowers the price target from $260 to $250.

AMAT

Evercore ISI Group Maintains Outperform on Applied Mat, Lowers Price Target to $250

TransDigm Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) short percent of float has risen 8.85% since its last report. The company recently reported that it has 889 thousand shares sold short, which is 2.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransDigm Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransDigm Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TransDigm Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransDigm Gr's peer group average for short interest as a percentage of float is 3.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About TransDigm Gr?

Dynatrace's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) short percent of float has fallen 5.26% since its last report. The company recently reported that it has 6.95 million shares sold short, which is 2.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dynatrace Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dynatrace has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Dynatrace's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dynatrace's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Dynatrace's Recent Short Interest

Carrier Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 10.17 million shares sold short, which is 1.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.41 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Carrier Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731678312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Carrier Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Carrier Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Carrier Global's peer group average for short interest as a percentage of float is 3.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

CARR

(CARR) - Analyzing Carrier Global's Short Interest

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) is &#8220;undervalued,&#8221; but he is not going to <a href="https://www.benzinga.com/quote/MO/guidance">recommend tobacco stocks</a>.
On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. It beat the street view of $1.35. Quarterly sales of $5.334 billion (+1.3%) beat the analyst consensus estimate of $5.326 billion.
Cramer recommended selling Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
Super Micro Computer filed a FormNT 10-Q with the Securities and Exchange Commission, indicating that it's unable to file its 2025 fiscal-year first-quarter earnings on time.
When asked about The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), he said, &#8220;I prefer not to be in a stock that is going to lose a lot of money for a long time.&#8221;
According to Reuters, the company reportedly begins issuing layoff notices to employees affected by a major restructuring plan. The plan, which aims to reduce Boeing's global workforce by 17,000 jobs—approximately 10% of its total—comes as the heavily indebted aerospace <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41950702/boeing-reportedly-plans-furloughs-whats-going-on">giant seeks to cut costs</a>.
Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) has &#8220;broken down severely,&#8221; Cramer said. &#8220;If Robert F. Kennedy Jr. is going to be the head of HHS, then it's going to hurt a lot of vaccines, it could hurt a lot of their business.&#8221;
On Nov. 7, the company posted better-than-expected results for its fourth quarter.
&#8220;They have a lot of phase one stuff, and phase one is might early. Too early for me to bet on,&#8221; Cramer said when asked about IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>).
On Nov. 4, IDEAYA Biosciences reported a quarterly loss of 60 cents per share, compared to consensus estimates of a loss of 64 cents per share.
&#8220;I just don't know what is wrong,&#8221; Cramer said about AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>). &#8220;My god is this thing going lower.&#8221;
On Nov. 12, AstraZeneca reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
Price Action:
<ul>
<li>Altria shares rose 0.3% to settle at $55.39 on Thursday.</li>
<li>Super Micro Computer shares dipped 11.4% to close at $18.01.</li>
<li>Boeing shares fell 1.3% to settle at $138.14 during the session.</li>
<li>Becton Dickinson shares fell 1.8% to close at $227.17 on Thursday.</li>
<li>IDEAYA Biosciences shares fell 3.4% to settle at $29.47 during the session.</li>
<li>AstraZeneca shares fell 0.4% to close at $65.04 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

IDYA

SMCI

Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It

October retail sales in the United States grew more than expected and their annual growth recorded the highest pace since July 2024, suggesting that U.S. consumers showed continued resilience in their spending habits ahead <a href="https://www.benzinga.com/topic/2024-election">of the presidential elections. </a>
Retail and food services sales reached $718.9 billion in October, marking a 0.4% increase over September. The figure is seasonally adjusted but not adjusted for inflation and is an advance estimate released by a government agency Friday. 
The monthly growth figure topped market expectations for a 0.3% increase, according to consensus estimates from TradingEconomics, but represented a deceleration from the upwardly revised 0.8% increase recorded in September.
<h3 class="wp-block-heading">Electronics Shopping Rebounds In October</h3>
On a year-over-year basis, retail sales grew by a robust 2.8%, the highest in three months and the second-strongest since April, up from the upwardly revised 2% in September. 
Excluding motor vehicles and parts, retail sales rose by just 0.1% month-over-month, down from the upwardly revised 1% growth in September, missing expectations of 0.3%. When stripping out gasoline, motor vehicles, and parts, sales inched 0.1% up in October, a noticeable deceleration from the 1.2% growth seen the previous month.
Within spending categories, electronic and appliance stores recorded the largest monthly gain, with sales increasing 2.3%, rebounding significantly from the 2.9% decline in September. 
Motor vehicle and parts dealers saw a 1.6% rise, accelerating from the previous 0.2% growth. 
On the other hand, miscellaneous store retailers registered the steepest monthly decline, with sales contracting 1.6%, followed closely by furniture and home furniture stores, which saw sales fall 1.3%.
Before the report's release, traders were pricing in a 58% probability of a 25-basis-point rate cut at the Federal Reserve's December meeting, according to the CME FedWatch Tool. 
Those expectations shifted substantially downward from about 80% after Fed Chair Jerome Powell stated on Thursday that the Federal Reserve is not in a hurry<a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates"> to lower interest rates. </a>
Powell also emphasized that the strength of the U.S. economy allows policymakers to approach rate decisions carefully, suggesting the potential for a pause in rate cuts.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a></li>
</ul>
Photo via Shutterstock.

Retail Sales

Econ #s

Economics

October Retail Sales Top Expectations As US Consumers Increase Tech Spending

On Friday, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 <a href="https://www.benzinga.com/pressreleases/24/11/g42000231/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urtic" target="_blank" rel="noreferrer noopener">antihistamine treatment</a>.
The target action date for the FDA decision is April 18, 2025.
Data from the multi-study LIBERTY-CUPID phase 3 clinical program (<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-07-29-05-00-00-2270858" rel="noreferrer noopener">Study A</a>,&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-18-06-00-00-2387700" rel="noreferrer noopener">Study B</a>, and&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-11-05-05-00-2944239" rel="noreferrer noopener">Study C</a>) for Dupixent in CSU support the resubmitted supplemental marketing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41945225/regeneron-sanofis-dupixent-approval-signals-major-treatment-breakthrough-for-smokers-lung-disease" rel="noreferrer noopener">Regeneron/Sanofi&#8217;s Dupixent Approval Signals Major Treatment Breakthrough For Smokers&#8217; Lung Disease</a>
Earlier this year, Japan was the first country in the world to&nbsp;approve&nbsp;and launch Dupixent for adult and adolescent CSU patients based on the results <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">from Study A</a>.
The supplemental marketing adds results from Study C, conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naïve patients, met its primary and key secondary endpoints, confirming the results of the previous Study A.
Results showed that Dupixent significantly reduced itch and urticaria activity (itch and hives).
In March 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670" rel="noreferrer noopener">accepted</a> the supplemental marketing application for Dupixent&nbsp;(dupilumab) to treat adults and adolescents with chronic spontaneous urticaria, with the target action date for the FDA decision of October 22, 2023.
In October 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252" rel="noreferrer noopener">issued</a> a Complete Response Letter for the supplemental Biologics License Application and stated that additional efficacy data are required to support approval.
It did not identify any issues with safety or manufacturing.
CSU is a chronic inflammatory skin disease driven partly by type-2 inflammation, which causes sudden hives and recurring itch.
CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control urticaria symptoms.
More than 300,000 people in the US suffer from CSU that is inadequately controlled by antihistamines.
Price Action: REGN stock closed at $782.51 on Thursday, and SNY stock is up 1.09% at $48.34 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape" target="_blank" rel="noreferrer noopener">UnitedHealth&#8217;s Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape</a></li>
</ul>
Photo: Shutterstock

Comments

Forward Pharma A/S ADR

Forward Pharma A/S ADR (FWPAY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO